Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Novartis to Construct $500M Biologics Plant in Singapore
Genetic Engineering News
Thursday, November 1, 2012 - 11:20am
tags:
Novartis, Singapore
Watson CEO Looks Past Actavis Deal to Next Growth Plans
Bloomberg
Thursday, November 1, 2012 - 11:19am
tags:
Watson, Pharma CEOs, Actavis, M&A, generics
Bayer to buy U.S. vitamin maker Schiff for $1.2 bln
Reuters
Thursday, November 1, 2012 - 11:18am
tags:
Bayer, M&A, Schiff, vitamins
GlaxoSmithKline warns on European drug prices
Guardian, UK
Thursday, November 1, 2012 - 11:17am
tags:
Europe, GSK, drug pricing
Isis Means Business With This New Treatment
Wall St. Cheat Sheet
Thursday, November 1, 2012 - 11:16am
tags:
Isis Pharmaceuticals, ISIS-STAT3, chemotherapy, advanced cancer, cancer
Somaxon Pharmaceuticals, Inc.'s CEO Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Thursday, November 1, 2012 - 11:15am
tags:
Somaxon, earnings
Pfizer sees emerging market sales rising in "high single digit" percentage range
Reuters
Thursday, November 1, 2012 - 11:14am
tags:
Pfizer, emerging markets
Eli Lilly: Cymbalta Patent Cliff
Seeking Alpha
Thursday, November 1, 2012 - 10:57am
tags:
patent cliff, Eli Lilly, Cymbalta
Pfizer Profit Matches Estimates as Forcast Range Narrows
Bloomberg
Thursday, November 1, 2012 - 10:08am
tags:
Pfizer, earnings
Neurocrine Biosciences' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Thursday, November 1, 2012 - 10:06am
tags:
earnings, Neurocrine Biosciences
Vertex to collaborate with Janssen on Phase 2 all-oral study for hepatitis C
The Fly on the Wall
Thursday, November 1, 2012 - 10:05am
tags:
Vertex, Janssen, hepatitis C, simeprevir, VX-135
Exelixis, Celgene, Gilead Sciences, Dynavax See Key Dates in November
Minyanville
Wednesday, October 31, 2012 - 11:52am
tags:
Exelixis, Celgene, Gilead, Dynavax
Cytokinetics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Wednesday, October 31, 2012 - 11:46am
tags:
earnings, Cytokinetics
BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA
Yahoo
Wednesday, October 31, 2012 - 11:45am
tags:
Biocryst, BCX5191, hepatitis C
Theravance's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Wednesday, October 31, 2012 - 11:43am
tags:
Theravance, earnings
Geron Management Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Wednesday, October 31, 2012 - 11:42am
tags:
earnings, Geron
FDA Releases its Briefing Concerning Rescheduling of Hydrocodone Combination Products in Advance of Advisory Committee Meeting
FDA Law Blog
Wednesday, October 31, 2012 - 11:41am
tags:
FDA, hydrocodone
3 Biotechs Investors Should Be Scared Of
Motley Fool
Wednesday, October 31, 2012 - 11:40am
tags:
Amarin, Alexion, Spectrum Pharmaceuticals
Biogen Idec's BG-12 PDUFA Delay is a Buying Opportunity
Yahoo/Reuters
Wednesday, October 31, 2012 - 11:38am
tags:
Biogen Idec, BG-12
Biogen Hemophilia A Therapy Helps in Fewer Injections
Bloomberg
Wednesday, October 31, 2012 - 11:37am
tags:
Biogen Idec, hemophilia, rFVIIIFc

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.